Navigation Links
EUSA Pharma Acquires Development and Commercialization Rights to ASPAREC® for Treatment of Acute Lymphoblastic Leukemia from Alizé Pharma
Date:2/2/2012

LANGHORNE, Pennsylvania and OXFORD, England, February 2, 2012 /PRNewswire/ --

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has acquired the exclusive worldwide development and commercialization rights to ASPAREC® for the treatment of acute lymphoblastic leukemia (ALL) from Alizé Pharma. Under the terms of the agreement, EUSA will pay Alizé Pharma an upfront fee, regulatory milestone payments and royalties on future product sales.  

ASPAREC is a recombinant, pegylated Erwinia chrysanthemi-derived asparaginase. It is currently in phase I development for the treatment of ALL in patients with hypersensitivity to standard-of-care E. coli-derived asparaginase therapy, and has been granted orphan status by the US and European regulatory authorities.  Preclinical data indicate that ASPAREC is potentially longer acting and less immunogenic than currently available asparaginase Erwinia chrysanthemi.

Commenting on the news, Bryan Morton, President and Chief Executive Officer of EUSA Pharma, said, "We are delighted to reach this agreement with Alizé Pharma.  ASPAREC fits perfectly with EUSA's specialty focus on oncology and orphan diseases, and builds on our established portfolio in the field of acute lymphoblastic leukemia.  This agreement follows the approval last year of EUSA's first internally developed product, and further underlines the company's strategic transition into a fully fledged development as well as commercialization organization."

"This agreement between Alizé Pharma and EUSA Pharma, a worldwide leader in the development and marketing of L-asparaginase products, is excellent news for us, for our investors and for ALL patients," said Alizé Pharma's President and founder, Thierry Abribat. "It validates our medical approach, emphasizes our drug development capabilities, and fits well with our business strategy, which is to establish partnerships with the pharmaceutical industry early in the development of our programs in order to secure both near-term and long-term revenue streams."

About acute lymphoblastic leukemia

Acute lymphoblastic leukemia is the most common form of childhood cancer, with approximately 2,900 patients under the age of 20 diagnosed in the USA each year [1].  It is also one of the most curable forms of cancer, with remission rates in treated children of over 95% and 75 - 85% surviving at least five years without recurrence of leukemia [1].  Treatment involves a number of stages and drugs, and typically includes asparaginase as an essential component of current protocols.  

About asparaginase and ASPAREC

Asparaginase enzymes deplete the level of asparagine in the bloodstream.  Asparagine is essential for cell growth, and its removal from the blood inhibits the growth of cells associated with acute lymphoblastic leukemia.  Asparaginase treatments are derived from bacteria, and approximately 15 - 20% of patients develop hypersensitivity to modern products derived from Escherichia coli, preventing their continued treatment [2].  ASPAREC is a proprietary recombinant, pegylated Erwinia chrysanthemi-derived asparaginase in development for the treatment of acute lymphoblastic leukemia in patients with hypersensitivity to E. coli-derived therapies.  Preclinical data indicate ASPAREC is potentially longer acting and less immunogenic than currently available asparaginase Erwinia chrysanthemi.  

About EUSA Pharma

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care products.  The company has an established commercial infrastructure in the US, a pan-European presence and a wider distribution network in numerous additional territories.  EUSA currently has a total of 10 specialist hospital products, which are sold in over 80 countries globally*.  These include Erwinase®/Erwinaze and Kidrolase® for the treatment of acute lymphoblastic leukemia, Caphosol® for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high dose chemotherapy, Collatamp® G, a surgical implant impregnated with the antibiotic gentamicin, ProstaScint® for imaging the extent and spread of prostate cancer and Quadramet® for the treatment of pain in patients whose cancer has spread to the bones.  The company also has a number of products in late-stage development.

References

[1] US National Cancer Institute.  Childhood acute lymphoblastic leukemia treatment (PDQ®). http://www.cancer.gov/cancertopics/pdq/treatment/childALL/HealthProfessional/page1

[2] Raetz EA, Salzer WL.  J Pediatr Oncol 2010:32:554-563.

* Not all products are approved currently for use in the US

Contacts
Bryan Morton    
Chief Executive    
EUSA Pharma    
Tel: +44(0)1865-784255    

Rob Budge
RJB Communications
Tel: +44(0)1865-760969
Mobile: +44(0)7710-741241



'/>"/>
SOURCE EUSA Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin
2. CVS/pharmacy Helps Customers Save Time with New Prescription Text Alerts
3. Valeant Pharmaceuticals Acquires Probiotica in Brazil
4. Shylendra Kumar Joins Pharmaceutical eConsulting
5. Worlds Leading Pharmaceutical Executives All Converging in Zurich, Switzerland on February 21-22, 2012 for Breakthrough Event
6. Innocoll Enters CollaGUARD® Distribution Partnership With Flynn Pharma Ltd in the UK and Inresa Arzneimittel GmbH in Germany
7. Auxilium Pharmaceuticals to Present at the Leerink Swann 2012 Global Healthcare Conference
8. Belvidere Pharmacy, Custom Medicine Makers, Moves to New, and Even Better, Home
9. Niiki Pharma Forms Scientific Advisory Board with Leading U.S. Oncologists
10. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
11. Kerry to Expand Center of Excellence with New Cell Science Laboratory Serving Bio-Pharma Customers Globally
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... develops, markets and sells medical devices and wearable sleep ... a strategic cooperation agreement with Hongyuan Supply Chain Management ... on June 20, 2016, to develop Dehaier,s new Internet ... agreement, Dehaier will leverage Hongyuan Supply Chain,s sales platform ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
Breaking Medicine News(10 mins):